Biotech Startups

Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform. The company serves the therapeutic development market with its targeted protein degradation approach.

1 investor

EnrollNow is a software platform for managing participant screening, enrollment, and study management across academic, clinical, and independent research programs. Originating from a University of Michigan research lab and licensed through Ripple Science Corporation, it is used by research teams globally and is HIPAA-compliant and SOC 2 certified.

1 investor

Ensem Therapeutics is a drug discovery and development company focused on oncology therapeutics, leveraging proprietary computational chemistry and protein structural dynamics platforms. The company advances small molecule and targeted therapies from discovery through clinical development.

1 investor

Clinical-stage biopharmaceutical company developing oral therapies for inflammatory bowel disease; based in New York, NY.

1 investor

ENTvantage Dx develops rapid, in-office diagnostic tests for primary care physicians and otolaryngologists to identify the causes of ear, nose, and throat illnesses. The company operates in the in-vitro diagnostics sector serving the medical diagnostics industry.

1 investor

Entact is a drug discovery company developing treatments for patients. It works in the biotechnology and therapeutics sector.

1 investor

Entasis Therapeutics is a biotechnology company developing and marketing therapies for critical care and infectious diseases, focusing on serious conditions with high unmet need. Its products include GIAPREZA, NUZOLVENCE, XACDURO, XERAVA, and ZEVTERA.

1 investor

Entegrion develops a point-of-care viscoelastic coagulation monitoring system (VCM) for rapid hemostasis assessment in clinical settings including trauma, surgery, and obstetrics. The company serves clinicians in civilian and military medicine, with regulatory clearance in Europe.

1 investor

Entelo Bio operates an insights platform that analyzes disease biology at high resolution to support precision medicine. The company focuses on applications in human resilience.

1 investor

1 investor

EnteroBiotix is a clinical-stage microbiome therapeutics company developing EBX-102-02, an orally delivered, full-spectrum microbiome drug for irritable bowel syndrome and other gastrointestinal and liver diseases. It uses proprietary AMPLA drying technology and MHRA-licensed GMP manufacturing, with a pipeline spanning IBS, liver cirrhosis, and adjuvant treatment in blood cancer.</parameter> <parameter name="founders">[]

1 investor

Entirety Biomedical develops absorbable metal surgical implants intended to replace permanent titanium hardware, providing fixation during healing and then absorbing into the body. Its implants target cosmetic, trauma, and reconstructive surgery procedures for surgeons and their patients.

1 investor

EntoGreen uses insects to bioconvert agricultural plant by-products into functional ingredients for animal feed, fat, and organic fertilizer through a circular, industrial-scale process. The company serves the agrifood industry and operates in Portugal.

1 investor

A research and development facility focused on continuous production and optimization of black soldier fly larvae for waste valorization and industrial scaling. The facility serves as Europe's first demonstration plant for this biotechnology process, supporting government authorities, suppliers, and potential investors.

1 investor

Countable Labs (formerly Enumerix) develops a digital PCR platform that performs genetic analysis with higher sensitivity, precision, and dynamic range than legacy PCR methods. The technology serves oncology, NIPT (non-invasive prenatal testing), infectious disease, and cell and gene therapy applications.

1 investor

Enuvio manufactures microfluidic devices for cell co-culture and compartmentalization research, including neuronal co-culture, axon guidance, and chemotaxis platforms for life sciences researchers.

1 investor

Envision Pharma Group provides strategic consulting and technology services to biopharma companies across asset strategy, product commercialization, medical affairs optimization, and revenue management. The company serves pharmaceutical manufacturers of all sizes with integrated services spanning clinical evidence generation, market access, compliance, and AI-driven platforms.

1 investor

Enzene Biosciences is a biologics company focused on the development and manufacturing of biopharmaceuticals. It is a subsidiary of Alkem Laboratories and offers advanced manufacturing processes as a strategic partner for biologic products.

1 investor

Enzidia operates an enzyme engineering platform that combines ultra-high-throughput screening (its MillionFull technology) with AI-directed evolutionary loops to optimize enzymes and cell factory strains for biomanufacturing. It partners with industrial biotech companies to improve bioprocess efficiency and generate large labeled enzyme sequence-performance datasets.

1 investor

Enzymatica develops health products that support the body's natural defenses against viruses, irritants, and microorganisms, including its ColdZyme mouth spray for treating and shortening the common cold. The company operates in the consumer healthcare and life sciences sector.

1 investor

Enzymlogic provides kinetic profiling of compounds to support early-stage drug discovery, focusing on the Hit to Lead and Lead Optimization phases. Using protein science and high-throughput screening assays, it delivers kinetic data on compound-target interactions to pharmaceutical and biotech organizations to help them prioritize promising molecules.

1 investor

Enzyva develops engineered enzyme systems that treat complex industrial wastewater in a single step under harsh conditions such as high pH, high salinity, and toxic chemicals. It initially targets textile industry effluents, with the aim of expanding to other water-intensive sectors including pharma, food, cosmetics, chemicals, and mining.

1 investor

Eon develops brain emulation technology, having built a digital emulation of a fruit fly brain — 139,255 neurons and 50 million connections preserved, scanned, and reconstructed — that reproduces biological neural responses and behaviors such as navigating, grooming, and feeding. The company aims to solve brain emulation as an engineering effort in the context of a future with superintelligence.

1 investor

Eos SENOLYTIX develops senolytic peptides designed to restore cellular balance in aged or senescent cells across body organs, focusing on gerotherapeutics. The company targets age-related conditions through proprietary approaches to cellular rejuvenation.

1 investor